Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers

Nonselective inverse agonists at the gamma-aminobutyric acid(A) (GABA-A) benzodiazepine binding site have cognition-enhancing effects in animals but are anxiogenic and can precipitate convulsions. Herein, we describe novel GABA-A alpha5 subtype inverse agonists leading to the identification of 16 as...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry Vol. 47; no. 9; pp. 2176 - 2179
Main Authors: Sternfeld, Francine, Carling, Robert W, Jelley, Richard A, Ladduwahetty, Tamara, Merchant, Kevin J, Moore, Kevin W, Reeve, Austin J, Street, Leslie J, O'Connor, Desmond, Sohal, Bindi, Atack, John R, Cook, Susan, Seabrook, Guy, Wafford, Keith, Tattersall, F David, Collinson, Neil, Dawson, Gerard R, Castro, José L, MacLeod, Angus M
Format: Journal Article
Language:English
Published: United States 22-04-2004
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nonselective inverse agonists at the gamma-aminobutyric acid(A) (GABA-A) benzodiazepine binding site have cognition-enhancing effects in animals but are anxiogenic and can precipitate convulsions. Herein, we describe novel GABA-A alpha5 subtype inverse agonists leading to the identification of 16 as an orally active, functionally selective compound that enhances cognition in animals without anxiogenic or convulsant effects. Compounds of this type may be useful in the symptomatic treatment of memory impairment associated with Alzheimer's disease and related dementias.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-2623